Illustration of the tumur microenvironment in triple-negative breast
Download scientific diagram | Illustration of the tumur microenvironment in triple-negative breast cancer. Notes: Data from Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Adapted from Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC. Eur Rev Med Pharmacol Sci. 2021;25(7):2885-2897. Creative Commons. 7 from publication: Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management | Triple negative breast cancer (TNBC) is a subtype of breast cancer which does not express or expresses a minimum amount of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) protein. TNBCs include a heterogenic group of | Breast Cancer Management, Triple Negative Breast Neoplasms and Tumor-Infiltrating Lymphocytes | ResearchGate, the professional network for scientists.
Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer - Nanoscale Horizons (RSC Publishing)
New Research: Tumor Cells Can Manipulate the Body's Natural Antibody Response to Triple Negative Breast Cancer - ChristianaCare News
Tumor Microenvironment in Triple Negative Breast Cancer
Frontiers Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes
Yale Cancer Center Study Explores New Path to Treat Advanced Triple-Negative Breast Cancer < Yale School of Medicine
Breast cancer microenvironment and obesity: challenges for therapy
Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy
